Mergers & Acquisitions - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

176 to 200 of 2711 results

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program

17-02-2014

Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

AVEO and Astellas finally terminate tivozanib collaboration

14-02-2014

US biotech firm AVEO Oncology and Japanese drug major Astellas Pharma are to end their worldwide collaboration…

Astellas PharmaAVEO OncologyBiotechnologyLicensingOncologytivozanib

Actelion’s Opsumit approved by SwissMedic for PAH patients

Actelion’s Opsumit approved by SwissMedic for PAH patients

14-02-2014

Swiss biotech firm Actelion announced today that SwissMedic has approved Opsumit (macitentan) for pulmonary…

ActelionBiotechnologyCardio-vascularNorthern EuropeOpsumitRegulation

NicOx appoints financial partner to assess Duchenne Muscular Dystrophy treatment

14-02-2014

French biotechnology firm NicOx (Euronext Paris: COX) has granted an undisclosed financial partner an…

BiotechnologyFranceGeneticsLicensingnaproxcinodNicOx

Kissei collaborates with Alteogen on biosimilars

14-02-2014

Japanese drugmaker Kissei Pharmaceutical has entered into a business collaboration agreement with South…

BiosimilarsBiotechnologyKissei PharmaceuticalResearch

Another milestone for GenVec in hearing and balance collaboration

13-02-2014

US biotech firm GenVec says it has achieved the third milestone in its collaboration with Swiss drug…

BiotechnologyCGF166FinancialGenVecLicensingNeurologicalNovartis

Retrophin to acquire Manchester Pharma in $62.5 million deal

Retrophin to acquire Manchester Pharma in $62.5 million deal

13-02-2014

USA-based Retrophin has signed an agreement to acquire Manchester Pharmaceuticals, a privately-held specialty…

Cardio-vascularChenodalManchester PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinVecamyl

Aurigene and Pierre Fabre announce licensing agreement for novel immunotherapy

Aurigene and Pierre Fabre announce licensing agreement for novel immunotherapy

13-02-2014

Privately-owned Pierre Fabre and Aurigene, a leading Indian biotech company, have entered into an agreement…

Aurigene DiscoveryBiotechnologyFranceIndiaLicensingOncologyPierre Fabre

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

13-02-2014

Exelixis (NASDAQ: EXEL) have announced the appointment of Jeffrey Hessekiel as executive vice president…

BiotechnologyBoardroomExelixisOncologyUSA

Health Canada approves Celgene’s Pomalyst for multiple myeloma

Health Canada approves Celgene’s Pomalyst for multiple myeloma

12-02-2014

Regulatory agency Health Canada has approved US biotech firm Celgene’s drug Pomalyst (pomalidomide…

BiotechnologyCanadaCelgeneNorth AmericaOncologyPomalystRegulation

Creation of ABIVAX - a leader in therapeutic vaccines - in a Cuban collaboration

12-02-2014

French venture capital firm Truffle Capital has announced the creation of Paris-based ABIVAX in collaboration…

ABIVAXAnti-viralsBiotechnologyResearchVaccines

Mallinckrodt to buy Cadence Pharma for around $1.3 billion

12-02-2014

Ireland-headquartered specialty drugmaker Mallinckrodt, spun off by Covidien last year, has entered into…

Cadence PharmaceuticalsMallinckrodtMergers & AcquisitionsOfirmevPharmaceutical

Increasing investment in Latin American pharma market

Increasing investment in Latin American pharma market

12-02-2014

Around $12.7 billion has been invested in Latin America’s pharmaceutical market through mergers and…

ArgentinaBrazilChileEcuadorFinancialMergers & AcquisitionsPharmaceuticalSouth America

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Nanobiotix outlines development plan for NBTXR3 in soft tissue sarcoma

11-02-2014

Nanobiotix, a French nanomedicine company focused on cancer therapy, has announced today its development…

BiotechnologyNanobiotixNBTXR3OncologyResearch

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

11-02-2014

US biotech major Gilead Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration…

Antibiotics and Infectious diseasesBiotechnologyGilead SciencesledipasvirRegulationsofosbuvirUSA

Alchemia announces appointment of Santo Costa as chairman

Alchemia announces appointment of Santo Costa as chairman

11-02-2014

Australia-based biotech company Alchemia has announced the appointment of Santo Costa as non-executive…

AlchemiaAustraliaBiotechnologyBoardroom

Actelion 2013 sales and earnings beat expectations

Actelion 2013 sales and earnings beat expectations

11-02-2014

Switzerland-based Actelion, Europe’s largest biotech firm, has reported financial results for full-year…

ActelionBiotechnologyFinancial

Mast Therapeutics to acquire Aires Pharma

10-02-2014

USA-based Mast Therapeutics has entered into a definitive agreement to acquire privately-held clinical-stage…

AIR001Aires PharmaceuticalsMast TherapeuticsMergers & AcquisitionsPharmaceuticalRespiratory and Pulmonary

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

Adcock Ingram and CFR Pharma call off merger

Adcock Ingram and CFR Pharma call off merger

10-02-2014

South Africa’s Adcock Ingram and Chile’s largest drugmaker CFR Pharmaceuticals have issued a joint…

Adcock IngramBidvestCFR PharmaceuticalsMergers & AcquisitionsPharmaceuticalRest of the WorldSouth Africa

Pharma M&A momentum expected to continue into 2014, says PwC

Pharma M&A momentum expected to continue into 2014, says PwC

10-02-2014

Pharmaceutical and life sciences (PLS) merger and acquisition (M&A) volume and value increased in the…

Mergers & AcquisitionsPharmaceutical

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

07-02-2014

Danish insulin giant Novo Nordisk has sold full development and commercialization rights to the anti-NKG2A…

anti-NKG2AInnate PharmaLicensingMergers & AcquisitionsNovo NordiskOncologyPharmaceutical

176 to 200 of 2711 results

Back to top